Molecular pathology of non-small cell lung cancer: A practical guide

American Journal of Clinical Pathology

Volumn 138, Issue 3, 2012, Pages 332-346

  Aisner, Dara L ^a   Marshall, Carrie B ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

ALK; EGFR; Molecular; Non small cell lung cancer; Specimen selection; Testing algorithm

Indexed keywords

ALK GENE; EGFR GENE; GENE; GENE MUTATION; GENE REARRANGEMENT; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG NEOPLASMS; MUTATION; PATHOLOGY, MOLECULAR; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84865427841     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPFR12WJKCEEZZ     Document Type: Review

References (132)

1. Ettinger DS, Akerley W, Bepler G, et al.Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8:740-801.
2. College of American Pathologists. Lung cancer biomarkers guideline draft recommendations. Available at: http://www.cap.org/apps/docs/membership/ transformation/new/lung-public-comment-supporting-materials.pdf. Accessed July 17, 2012.
3. Gaughan EM, Costa DB. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol. 2011;3:113-125.
4. Rosell R, Moran T, Queralt C, et al.Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958-967.
5. Gandhi L, Jänne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target [published online ahead of print June 21, 2012]. Clin Cancer Res.
6. Cheng H, Xu X, Costa DB, et al.Molecular testing in lung cancer: the time is now. Curr Oncol Rep. 2010;12:335-348.
7. Keedy VL, Temin S, Somerfield MR, et al.American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29:2121-2127.
8. Anderson SM. Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn. 2011;11:635-642.
9. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res. 2007;13:4954-4955. (Pubitemid 47502057)
10. John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene. 2009;28(suppl 1):S14-S23.
11. Aisner DL, Sams SB. The role of cytology specimens in molecular testing of solid tumors: techniques, limitations, and opportunities. Diagn Cytopathol. 2012;40:511-524.
12. Jemal A, Bray F, Center MM, et al.Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
13. Siegel R, Ward E, Brawley O, et al.Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
14. Jemal A, Thun M, Yu XQ, et al.Changes in smoking prevalence among U.S. adults by state and region: estimates from the Tobacco Use Supplement to the Current Population Survey, 1992-2007. BMC Public Health. 2011;11:512.
15. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007;25:561-570. (Pubitemid 350002964)
16. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers: a different disease. Nat Rev Cancer. 2007;7:778-790. (Pubitemid 47463669)
17. Black C, Bagust A, Boland A, et al.The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technol Assess. 2006;10:iii-iv, ix-x, 1-90.
18. Bach PB, Kelley MJ, Tate RC, et al.Screening for lung cancer: a review of the current literature. Chest. 2003;123(suppl):72S-82S. (Pubitemid 36135704)
19. Infante M, Cavuto S, Lutman FR, et al.A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009;180:445-453.
20. National Cancer Institute. SEER Stat Fact Sheet: Lung and Bronchus. Available at: http://seer.cancer.gov/statfacts/html/lungb.html. Accessed July 17, 2012.
21. Aberle DR, Adams AM, Berg CD, et al.Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
22. Bach PB, Mirkin JN, Oliver TK, et al.Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307:2418-2429.
23. Travis WD, Brambilla E, Noguchi M, et al.International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
24. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med. 2011;32:22-31.
25. Langer CJ, Besse B, Gualberto A, et al.The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:5311-5320.
26. Shigematsu H, Lin L, Takahashi T, et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339-346. (Pubitemid 40425952)
27. Toyooka S, Matsuo K, Shigematsu H, et al.The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res. 2007;13:5763-5768. (Pubitemid 47583901)
28. Lynch TJ, Bell DW, Sordella R, et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139. (Pubitemid 38637993)
29. Paez JG, Janne PA, Lee JC, et al.EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. (Pubitemid 38720929)
30. Sartori G, Cavazza A, Sgambato A, et al.EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol. 2009;131:478-489.
31. Rickman OB, Vohra PK, Sanyal B, et al.Analysis of ErbB receptors in pulmonary carcinoid tumors. Clin Cancer Res. 2009;15:3315-3324.
32. Wislez M, Antoine M, Baudrin L, et al.Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer. 2010;68:185-191.
33. Rodig SJ, Mino-Kenudson M, Dacic S, et al.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15:5216-5223.
34. Takahashi T, Sonobe M, Kobayashi M, et al.Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17:889-897.
35. Pillai RN, Ramalingam SS. The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation. Curr Oncol Rep. 2012;14:105-110.
36. D'Angelo SP, Pietanza MC, Johnson ML, et al.Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol. 2011;29:2066-2070.
37. Pham D, Kris MG, Riely GJ, et al.Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006;24:1700-1704. (Pubitemid 46622141)
38. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer. 2012;106:1100-1106.
39. Weickhardt AJ, Camidge DR. The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. Clin Invest. 2011;1:1119-1126.
40. Dacic S, Shuai Y, Yousem S, et al.Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol. 2010;23:159-168.
41. Langer CJ. Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges. Crit Rev Oncol Hematol. 2012;83:130-144.
42. Wong DW, Leung EL, So KK, et al.The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723-1733.
43. Sasaki T, Rodig SJ, Chirieac LR, et al.The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010;46:1773-1780.
44. Soda M, Choi YL, Enomoto M, et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566. (Pubitemid 47206930)
45. Cui JJ, Tran-Dube M, Shen H, et al.Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011;54:6342-6363.
46. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther. 2011;5:471-485.
47. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, et al.Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 2012;7:1086-1090.
48. Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 2010;11:1477-1490.
49. Camidge DR, Bang YJ, Kwak EL, et al.Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2011;29:a2501.
50. Kim DW, Ahn M, Shi Y, et al.Results of a global phase II study with crizotinib in advanced ALK positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30. Abstract 7533.
51. Camidge DR, Kono SA, Lu X, et al.Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011;6:774-780.
52. Lee JO, Kim TM, Lee SH, et al.Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol. 2011;6:1474-1480.
53. Roberts PJ, Stinchcombe TE, Der CJ, et al.Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol. 2010;28:4769-4777.
54. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009;6:201-205.
55. Riely GJ, Kris MG, Rosenbaum D, et al.Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14:5731-5734.
56. Ahrendt SA, Decker PA, Alawi EA, et al.Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001;92:1525-1530. (Pubitemid 32947838)
57. Benesova L, Minarik M, Jancarikova D, et al.Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. Anticancer Res. 2010;30:1667-1671.
58. Engelman JA, Zejnullahu K, Mitsudomi T, et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-1043. (Pubitemid 46799492)
59. Bean J, Brennan C, Shih JY, et al.MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007;104:20932-20937.
60. Turke AB, Zejnullahu K, Wu YL, et al.Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17:77-88.
61. Beau-Faller M, Ruppert AM, Voegeli AC, et al.MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J Thorac Oncol. 2008;3:331-339. (Pubitemid 351489471)
62. Witt BL, Wallander ML, Layfield LJ, et al.Respiratory cytology in the era of molecular diagnostics: a review. Diagn Cytopathol. 2012;40:556-563.
63. Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(suppl):131S-148S. (Pubitemid 47502804)
64. Pirker R, Herth FJ, Kerr KM, et al.Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010;5:1706-1713.
65. Ellis PM, Blais N, Soulieres D, et al.A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol. 2011;6:1379-1391.
66. Gridelli C, De Marinis F, Di Maio M, et al.Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: implications for clinical practice and open issues. Lung Cancer. 2011;72:3-8.
67. Ohtsuka K, Ohnishi H, Fujiwara M, et al.Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer. 2007;109:741-750. (Pubitemid 46233236)
68. Klempner SJ, Cohen DW, Costa DB. ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. J Thorac Oncol. 2011;6:1439-1440.
69. Kang SM, Kang HJ, Shin JH, et al.Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer. 2007;109:581-587. (Pubitemid 46190967)
70. Jia XL, Chen G. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. Lung Cancer. 2011;74:396-400.
71. Tochigi N, Dacic S, Nikiforova M, et al.Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population. Am J Clin Pathol. 2011;135:783-789.
72. Rekhtman N, Paik PK, Arcila ME, et al.Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012;18:1167-1176.
73. Tanaka K, Hata A, Kida Y, et al.Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation. Intern Med. 2012;51:659-661.
74. Zhang D, Takigawa N, Ochi N, et al.Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung. Lung Cancer. 2011;73:379-380.
75. Park SH, Ha SY, Lee JI, et al.Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. J Korean Med Sci. 2009;24:448-452.
76. Miyamae Y, Shimizu K, Hirato J, et al.Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep. 2011;25:921-928.
77. Thunnissen E, Kerr KM, Herth FJ, et al.The challenge of NSCLC diagnosis and predictive analysis on small samples: practical approach of a working group. Lung Cancer. 2012;76:1-18.
78. da Cunha Santos G, Lai SW, Saieg MA, et al.Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype [published online ahead of print May 30, 2012]. Lung Cancer.
79. Chaft JE, Rekhtman N, Ladanyi M, et al.ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. J Thorac Oncol. 2012;7:768-769.
80. Mino-Kenudson M, Mark EJ. Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Arch Pathol Lab Med. 2011;135:655-664.
81. D'Angelo SP, Park B, Azzoli CG, et al.Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. J Thorac Cardiovasc Surg. 2011;141:476-480.
82. Girard N, Deshpande C, Azzoli CG, et al.Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest. 2010;137:46-52.
83. Warth A, Macher-Goeppinger S, Muley T, et al.Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy. Eur Respir J. 2012;39:1437-1442.
84. Ma ES, Cheng PN, Wong CL, et al.Synchronous primary lung cancer and epidermal growth factor receptor mutation. Ann Thorac Surg. 2010;90:e38-e39.
85. Takamochi K, Oh S, Matsuoka J, et al.Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. Lung Cancer. 2012;75:313-320.
86. Gerlinger M, Rowan AJ, Horswell S, et al.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.
87. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol. 2011;29:2972-2977.
88. Camidge DR, Kono SA, Flacco A, et al.Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010;16:5581-5590.
89. Sun PL, Seol H, Lee HJ, et al.High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol. 2012;7:323-330.
90. Chen ZY, Zhong WZ, Zhang XC, et al.EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas [published online ahead of print June 6, 2012]. Oncologist.
91. Monaco SE, Nikiforova MN, Cieply K, et al.A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol. 2010;41:94-102.
92. Kalikaki A, Koutsopoulos A, Trypaki M, et al.Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008;99:923-929.
93. Han HS, Eom DW, Kim JH, et al.EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer. 2011;12:380-386.
94. da Cunha Santos G, Saieg MA, Geddie W, et al.EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol. 2011;119:80-91.
95. Malapelle U, Bellevicine C, Zeppa P, et al.Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. Diagn Cytopathol. 2011;39:703-710.
96. Rekhtman N, Brandt SM, Sigel CS, et al.Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6:451-458.
97. Aisner DL, Deshpande C, Baloch Z, et al.Evaluation of EGFR mutation status in cytology specimens: an institutional experience [published online ahead of print November 18, 2011]. Diagn Cytopathol.
98. Betz BL, Roh MH, Weigelin HC, et al.The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol. 2011;136:564-571.
99. Malapelle U, de Rosa N, Rocco D, et al.EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study. J Clin Pathol. 2012;65:87-91.
100. Killian JK, Walker RL, Suuriniemi M, et al.Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn. 2010;12:739-745.
101. Billah S, Stewart J, Staerkel G, et al.EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol. 2011;119:111-117.
102. Terry J, Leung S, Laskin J, et al.Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010;34:1805-1811.
103. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol. 2011;35:15-25.
104. Oxnard GR, Arcila ME, Chmielecki J, et al.New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res. 2011;17:5530-5537.
105. Doebele RC, Pilling AB, Aisner DL, et al.Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18:1472-1482.
106. Katayama R, Shaw AT, Khan TM, et al.Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012;4:120ra117.
107. Carter CA, Giaccone G. Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors. Curr Opin Oncol. 2012;24:123-129.
108. Suda K, Murakami I, Katayama T, et al.Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 2010;16:5489-5498.
109. Pao W, Miller VA, Politi KA, et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.
110. Sequist LV, Waltman BA, Dias-Santagata D, et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
111. Hunt JL, Finkelstein SD. Microdissection techniques for molecular testing in surgical pathology. Arch Pathol Lab Med. 2004;128:1372-1378. (Pubitemid 39627474)
112. Kris MG, Johnson B, Kwiatkowski D, et al.Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol. 2011;29(suppl). Abstract CRA7506.
113. Johnson B, Kris MG, Kwiatkowski D, et al.Clinical characteristics of planned 1000 patients with adenocarcinoma of lung (ACL) undergoing genomic characterization in the US Lung Cancer Mutation Consortium (LCMC). Presented at the 14th World Conference on Lung Cancer; July 5, 2011; Amsterdam, the Netherlands.
114. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175-180.
115. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med. 2012;18:349-351.
116. Capelletto E, Novello S. Emerging new agents for the management of patients with non-small cell lung cancer. Drugs. 2012;72(suppl 1):37-52.
117. Ausborn NL, Le QT, Bradley JD, et al.Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 2012;83:e453-e464.
118. Janku F, Garrido-Laguna I, Petruzelka LB, et al.Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol. 2011;6:1601-1612.
119. Bergethon K, Shaw AT, Ou SH, et al.ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-870.
120. Davies KD, Le AT, Theodoro MF, et al.Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012. In press.
121. Shaw A, Camidge DR, Engelman JA, et al.Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol. 2012;20. Abstract 7508
122. Paik PK, Arcila ME, Fara M, et al.Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29:2046-2051.
123. Marchetti A, Felicioni L, Malatesta S, et al.Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574-3579.
124. Weiss J, Sos ML, Seidel D, et al.Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2:62ra93.
125. Ramieri MT, Murari R, Botti C, et al.Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma. Anticancer Res. 2010;30:1287-1292.
126. Junker K, Stachetzki U, Rademacher D, et al.HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. Lung Cancer. 2005;48:59-67. (Pubitemid 40381000)
127. Li C, Sun Y, Fang R, et al.Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol. 2012;7:85-89.
128. Tomizawa K, Suda K, Onozato R, et al.Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer. 2011;74:139-144.
129. Shigematsu H, Takahashi T, Nomura M, et al.Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005;65:1642-1646. (Pubitemid 40478587)
130. Kawano O, Sasaki H, Endo K, et al.PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer. 2006;54:209-215. (Pubitemid 44764916)
131. Califano R, Landi L, Cappuzzo F. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs. 2012;72(suppl 1):28-36.
132. Janne PA, Shaw A, Pereira JR, et al.Phase II double-blind, randomized study of selemetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;20(suppl). Abstract 7503